[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-360358-105":59,"doc-detail-360358-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","evaluation-of-the-diagnostic-value-of-three-yidixie-tests-in-prostate-cancer-an-observational-prospective-single-center-study","Evaluation of the diagnostic value of three YiDiXie tests in prostate cancer - an observational prospective single-center study","","Prostate-Specific Antigen (PSA) and Magnetic Resonance Imaging (MRI) are widely used for prostate cancer (PCa) diagnosis but can yield inaccurate results that affect care. This observational prospective single-center study evaluated the diagnostic value of YiDiXie-30, YiDiXie-32, and YiDiXie-48. A total of 562 participants were included, and residual serum samples were tested to calculate sensitivity, specificity, PLR, and NLR using ROC analyses. Results showed strong diagnostic utility with distinct performance across tests.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/evaluation-of-the-diagnostic-value-of-three-yidixie-tests-in-prostate-cancer-an-observational-prospective-single-center-study/360358/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/evaluation-of-the-diagnostic-value-of-three-yidixie-tests-in-prostate-cancer-an-observational-prospective-single-center-study/360358.png","ImageObject",300,407,{"name":92,"@type":93},"McQueen","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the purpose of evaluating the YiDiXie tests in this study?","Question",{"text":112,"@type":113},"To assess the diagnostic value of YiDiXie-30, YiDiXie-32, and YiDiXie-48 for prostate cancer and to address false-positive and false-negative issues associated with PSA or MRI.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How many participants were included and how were they classified?",{"text":117,"@type":113},"The study included 562 participants, comprising a malignant group of 357 and a benign group of 205.",{"name":119,"@type":110,"acceptedAnswer":120},"Which diagnostic performance measures were calculated for YiDiXie-30, YiDiXie-32, and YiDiXie-48?",{"text":121,"@type":113},"Sensitivity, specificity, positive likelihood ratio (PLR), and negative likelihood ratio (NLR) were calculated, with Receiver Operating Characteristic (ROC) curve analyses included.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},360358,1790950681,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},5909890329169,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nEvaluation of the diagnostic value of three YiDiXie tests in prostate cancer: an observational prospective single-center study  \nXutai Li1,2,3,4,9, Chen Sun1,2,3,4,9, Shengjie Lin1,2,3,6, Zhenjian Ge1,2,3,5, Pengwu Zhang1,2,3, Wuping Wang1,2,3,7, Siwei Chen1,2,3,7, Yutong Wu1,2,3,6, Huimei Zhou1,2,3,4, Rong Huang8􀀍, Liangchao Ni1,2,3􀀍 & Yongqing Lai1,2,3,4􀀍  \nProstate-Specific Antigen (PSA) and Magnetic Resonance Imaging (MRI) are widely used in the diagnosis of prostate cancer (PCa), but relatively inaccurate results may affect diagnosis and treatment. There is an urgent need to find convenient, economical and non-invasive diagnostic methods to reduce the false positive and false negative rates of PSA or MRI. The purpose of this study was to evaluate the diagnostic value of YiDiXie-30, YiDiXie-32, andYiDiXie-48 in prostate cancer.  \nThis study ultimately included 562 participants (malignant group, n = 357; benign group, n = 205) . Residual serum samples from the participants were collected and tested using theYiDiXie all-cancer detection kit to assess the sensitivity, specificity, positive likelihood ratio(PLR) and negative likelihood ratio(NLR) of YiDiXie-30, YiDiXie-32 andYiDiXie-48, respectively. Receiver-operating characteristic (ROC) curves’ analyses were included in this study. The sensitivity of YiDiXie-30 was 81.2%, with a specificity of 93.2%, positive likelihood ratio (PLR) of 11.9, and negative likelihood ratio (NLR) of 0.20. Corresponding values for YiDiXie-32 were 93.6%, 85.4%, 6.4, and 0.08, while those for YiDiXie-48 were 99.4%, 61.5%, 2.6, and 0.01, respectively. Further studies found that YiDiXie-30, YiDiXie-32, and YiDiXie-48 yielded similar results in patients with positive or negative PSA or MRI. The results of the single-center study showed that theYiDiXie tests were highly effective in diagnosing prostate cancer, with clearly different levels of sensitivity and specificity. TheYiDiXie tests show strong diagnostic utility for prostate cancer within the particular clinical and population context of this study cohort, especially theYiDiXie-30 (extremely high PLR) andYiDiXie-48 ((extremely low NLR). This method has the potential to significantly reduce needless biopsies brought on by false-positive PSA or MRI results. The two main issues of“excessively high false-positive rates” and “excessively high false-negative rates” in PSA or MRI are anticipated to be addressed.  \nClinical Research Registry Number: ChiCTR2200066840 .  \nKeywords Prostate cancer, YiDiXie™, miRNA biomarkers, Serum, Tumor  \nProstate cancer (PCa) is one of the most common malignant tumors. In 2022, there were approximately 1.5 million new cases of PCa globally, with 397,000 new deaths1. Compared to 2020, the incidence and mortality rates of PCa increased by 3.71% and 5.72%, respectively, in 20221,2. If detected and diagnosed through early screening, the 10-year survival rate for patients with localized PCa can reach up to 99% . However, for men diagnosed with advanced disease (distant metastasis), the 5-year overall survival rate is only 30%3,4. Therefore, PCa poses a serious threat to human health.  \n1Department of Urology, Peking University Shenzhen Hospital, The Fifth Clinical Medical College of Anhui Medical University, 1120 Lianhua Road, Shenzhen 518036, China. 2Institute of Urology, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center, Shenzhen 518036, China. 3Shenzhen Clinical Research Center for Urology and Nephrology, Shenzhen 518036, China. 4The Fifth Clinical Medical College of Anhui Medical University, Hefei, China. 5Department of Urology, Shenzhen Xinhua Hospital, Shenzhen 518055, China.  \n6PKU-Shenzhen Clinical Institute of Shantou University Medical College, Shenzhen 518036, China. 7Shenzhen University Health Science Center, Shenzhen 518036, China. 8Department of Medical Imaging, Peking University Shenzhen H","cbCaihEx54YZQAyP","https://ap.wps.com/l/cbCaihEx54YZQAyP","pdf",1905399,"English","# Background\n## Diagnostic limits of PSA and MRI\n# Study Design\n## Participants and sample collection\n## YiDiXie testing and performance metrics\n# Results\n## Sensitivity, specificity, PLR, and NLR\n## Utility in PSA/MRI positive or negative contexts\n# Clinical Implications\n## Potential to reduce unnecessary biopsies","[{\"question\":\"What was the purpose of evaluating the YiDiXie tests in this study?\",\"answer\":\"To assess the diagnostic value of YiDiXie-30, YiDiXie-32, and YiDiXie-48 for prostate cancer and to address false-positive and false-negative issues associated with PSA or MRI.\"},{\"question\":\"How many participants were included and how were they classified?\",\"answer\":\"The study included 562 participants, comprising a malignant group of 357 and a benign group of 205.\"},{\"question\":\"Which diagnostic performance measures were calculated for YiDiXie-30, YiDiXie-32, and YiDiXie-48?\",\"answer\":\"Sensitivity, specificity, positive likelihood ratio (PLR), and negative likelihood ratio (NLR) were calculated, with Receiver Operating Characteristic (ROC) curve analyses included.\"}]","Evaluation of the diagnostic value of three YiDiXie tests in prostate cancer - an observational prospective single-center study | PDF",1790139780,25,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/25658c269576b43ac43b7f8a467ec54b.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bb839707e778576cca73ac9a3855f9c6.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9ab0dcb67ee5bab5564f2a2d261b65e6.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2e394871a0a940491929186a0343d40a.webp",980,1287]